ZVRA Stock Risk & Deep Value Analysis
Zevra Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About ZVRA Stock
We analyzed Zevra Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ZVRA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate-Aggressive. Here's what we found.
ZVRA Risk Analysis & Red Flags
What Could Go Wrong
The company's future growth largely hinges on successful clinical development of its pipeline assets, particularly DiSCOVER Phase 3 results or arimoclomol EMA approval, or a highly accretive M&A deal. Failure in a key trial, or an ill-conceived acquisition using the $236.8 million cash, could severely undermine its 10x growth potential and current valuation.
Risk Matrix
Overall
Moderate-Aggressive
Financial
Low
Market
Low
Competitive
Medium
Execution
Medium
Regulatory
High
Red Flags
- ⚠
Q1 2026 net income heavily reliant on one-time $43.3M gain from asset sale, masking true organic profitability.
- ⚠
Heavy reliance on a small number of approved drugs, with MIPLYFFA being the primary revenue driver mentioned.
- ⚠
Lack of specific competitive landscape data in provided research makes comprehensive peer analysis difficult.
- ⚠
Biotech sector inherent high regulatory risk and binary clinical trial outcomes.
Upcoming Risk Events
- 📅
Negative DiSCOVER Phase 3 trial results (expected 6-18 months): Failure would eliminate significant future revenue potential and lead to a substantial stock price decline (est. 20-30% downside).
- 📅
Ineffective deployment of $236.8M cash for M&A or R&D (ongoing): Acquisition of a non-accretive asset or continued cash burn without significant pipeline progress could negatively impact investor sentiment and valuation.
When to Reconsider
- 🚪
Exit if quarterly MIPLYFFA revenue declines YoY (below Q1 2026's $24.6M, excluding one-time gains).
- 🚪
Sell if a lead pipeline asset (e.g., DiSCOVER) reports negative Phase 3 trial results.
- 🚪
Exit if cash and cash equivalents drop below $100M without clear, imminent pipeline success or M&A.
Unlock ZVRA Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Zevra Therapeutics Inc (ZVRA) Do?
Market Cap
$643.17M
Sector
Healthcare
Industry
Biotechnology
Employees
59
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
Visit Zevra Therapeutics Inc WebsiteInvestment Thesis
If Zevra successfully advances one or more of its rare disease pipeline assets (e.g., positive DiSCOVER Phase 3 results, arimoclomol EMA approval) within the next 18-24 months, and/or executes an accretive acquisition using its $236.8 million net cash, then its annual revenue run-rate could exceed $200-$300 million by 2028, leading to a significant re-rating of its market capitalization from $0.69B to over $2B (3-5x current) on projected peak sales, setting the stage for 10x growth with further pipeline/M&A success. This is bullish because the current valuation does not fully price in the transformative potential of pipeline successes or strategic M&A, especially with its de-risked balance sheet.
Is ZVRA Stock Undervalued?
Unlock the full AI analysis for ZVRA
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
ZVRA Price Targets & Strategy
12-Month Target
$22.50
Bull Case
$35.00
Bear Case
$8.00
Valuation Basis
Based on 4.5x EV/FY27 est. revenue of $150M + current cash, reflecting successful MIPLYFFA growth and pipeline progress.
Entry Strategy
Dollar-cost average between $10.00-$11.00 (near current levels, considering strong balance sheet).
Exit Strategy
Take 50% profit at $20.00; Stop loss at $8.50 (below recent support levels).
Portfolio Allocation
7-10% for aggressive risk tolerance, given the high-risk/high-reward biotech profile.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is ZVRA Financially Healthy?
Valuation
P/E Ratio
5.18
Forward P/E
17.82
EV/EBITDA
4.00
PEG Ratio
0.03
Price/Book
3.52
Price/Sales
5.53
Profitability
Gross Margin
97.90%
Operating Margin
-4.44%
Net Margin
101.58%
Return on Equity
81.34%
Revenue Growth
201.29%
EPS
$2.15
Balance Sheet
Current Ratio
5.68
Quick Ratio
5.46
Debt/Equity
0.40
Total Debt
$62.72M
Cash & Equivalents
$199.51M
Cash Flow
Operating Cash Flow
-$23.36M
Free Cash Flow
-$24.23M
EBITDA
-$80.61M
Other
Beta (Volatility)
0.92
Does ZVRA Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
Patents and orphan drug exclusivity provide a durable, but time-limited, moat. Successful development of new drugs and strategic acquisitions are crucial for long-term moat expansion, extending the period of exclusivity and market protection.
Moat Erosion Risks
- •Patent expiry for existing commercialized drugs like MIPLYFFA.
- •Competitive entry with superior or cheaper alternatives in its therapeutic areas.
- •Clinical trial failures for pipeline assets, preventing new IP from forming a moat.
ZVRA Competitive Moat Analysis
Sign up to see competitive advantages
ZVRA Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral; generally attracts speculative retail interest due to biotech catalysts.
Institutional Sentiment
Neutral; Q1 earnings beat could prompt positive re-evaluation by institutions, but no specific upgrades/downgrades were available in the research.
Insider Activity (Form 4)
I could not verify any Form 4 insider transactions from the provided results. No CEO/CFO purchase or sale activity was available in the supplied search set.
Options Flow
Normal options activity; no specific unusual options activity was provided in the research.
Earnings Intelligence
Next Earnings
Estimated early August 2026 (for Q2 2026 results).
Surprise Probability
Medium; Q1 beat estimates, but future organic growth consistency without one-time gains will be key.
Historical Earnings Pattern
Q1 2026 earnings beat resulted in positive sentiment, suggesting the stock typically reacts positively to strong operational and financial beats.
Key Metrics to Watch
Competitive Position
Top Competitor
Could not be definitively identified from the provided research. General rare disease pharma peers include BioMarin Pharmaceutical (BMRN) or Sarepta Therapeutics (SRPT).
Market Share Trend
Stable; no specific market share data was provided in the research, but MIPLYFFA is contributing significantly to revenue.
Valuation vs Peers
Without specific valuation metrics (P/E, EV/EBITDA, P/S) for Zevra in the research, a direct comparison is not possible. However, given its small-cap status and high growth potential in rare diseases, it may trade at a premium on a future-looking basis or at a discount reflecting pipeline risk.
Competitive Advantages
- •Orphan drug designations for specific indications (implied for rare disease drugs).
- •Strong net cash position ($236.8M) enabling strategic M&A and R&D investments.
- •Existing commercial infrastructure for MIPLYFFA, providing a base for future product launches.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive ZVRA Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 earnings (estimated early August 2026): Key metric to watch is organic MIPLYFFA revenue growth, excluding one-time gains, with a target of >20% YoY growth.
- •Arimoclomol EMA review decision (if expected in H2 2026): Positive decision could unlock significant European market potential, adding an estimated $50M-$100M to peak sales potential.
Medium-Term (6-18 months)
- •DiSCOVER Phase 3 trial data readout (expected 6-18 months): Positive results would validate potential for a new rare disease asset, potentially adding $200M-$500M to peak sales estimates and significantly re-rating the stock.
- •Strategic M&A announcement (next 12-18 months): Deployment of $236.8M cash to acquire a value-accretive rare disease asset or pipeline, with an aim to add >$50M in annual revenue by FY2028.
Long-Term (18+ months)
- •Full commercialization of new pipeline drug(s) (e.g., from DiSCOVER or M&A) reaching $200M+ in annual peak sales by 2029-2030, driving significant revenue and market cap expansion.
- •Expansion of MIPLYFFA into new geographies or additional indications by 2030, potentially doubling its current revenue contribution.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for ZVRA?
- ✓
Watch quarterly MIPLYFFA revenue growth, ensuring sustained organic growth >20% YoY (excluding one-time gains).
- ✓
Monitor announcements regarding DiSCOVER Phase 3 trial results or arimoclomol regulatory approval status.
- ✓
Track cash utilization for M&A – specifically, details of any acquisitions and their projected revenue/profitability contribution.
Bull Case Analysis
Sign up free to see the bull case
Competing with ZVRA
See how Zevra Therapeutics Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Zevra Therapeutics Inc ZVRA | $643.2M | 8.8 | 5.2 | $84.4M | 101.6% | 201.3% | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Zevra Therapeutics Inc Makes Money
Zevra Therapeutics is a specialty pharmaceutical company focused on developing and commercializing therapies for rare diseases. It primarily generates revenue from the sale of its approved products, notably MIPLYFFA for a specific rare neurological condition, along with other therapies like OLPRUVA and royalties from AZSTARYS. The company aims to expand its portfolio through internal pipeline development and strategic acquisitions, leveraging its strong balance sheet to address unmet medical needs in niche, high-value markets.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Zevra Therapeutics Inc (ZVRA)?
As of June 3, 2026, Zevra Therapeutics Inc has a DVR Score of 8.8 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Zevra Therapeutics Inc?
Zevra Therapeutics Inc's market capitalization is approximately $643.2M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Zevra Therapeutics Inc use?
ZVRA is the ticker symbol for Zevra Therapeutics Inc. The company trades on the NMS.
What is the risk level for ZVRA stock?
Our analysis rates Zevra Therapeutics Inc's overall risk as Moderate-Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of ZVRA?
Zevra Therapeutics Inc currently has a price-to-earnings (P/E) ratio of 5.2. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Zevra Therapeutics Inc's revenue growing?
Zevra Therapeutics Inc has reported revenue growth of 201.3%. The company is showing strong top-line momentum.
Is ZVRA stock profitable?
Zevra Therapeutics Inc has a profit margin of 101.6%. This indicates strong profitability.
How often is the ZVRA DVR analysis updated?
Our AI-powered analysis of Zevra Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 3, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ZVRA (Zevra Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.